The DoW's first Phase 3-specific funding tranche validates the AP-SA02 program's regulatory and clinical progress. Monitor for additional DoW funding commitments and Phase 3 trial initiation in H2 2026, which could further extend cash runway without shareholder dilution.
Price Chart
Executive Summary
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of its lead candidate AP-SA02 for Staphylococcus aureus bacteremia. This brings total DoW funding for the program to approximately $32.4 million, representing the first Phase 3-specific tranche under a previously announced award.
Key Facts
- Received $3.7 million in additional non-dilutive funding from the U.S. Department of War
- Funding is specifically for Phase 3 execution of AP-SA02 (S. aureus bacteremia)
- Cumulative DoW funding under the award now totals approximately $32.4 million
- AP-SA02 has FDA Breakthrough Therapy, Fast Track, and QIDP designations
- Phase 3 study anticipated to initiate in the second half of 2026
Financial Impact
$3.7 million non-dilutive funding received; cumulative DoW funding ~$32.4 million
Risk Factors
- Phase 3 trial execution risk and potential for negative results
- Reliance on continued government funding for full Phase 3 program
- Late-stage clinical-stage biotech with no approved products or revenue
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-109809 |
| Document: tm2625977d1_ex99-1.htm | 0001104659-26-109809 |
| Document: 0001104659-26-109809-index-headers.html | 0001104659-26-109809 |
| Document: 0001104659-26-109809-index.html | 0001104659-26-109809 |
| Document: 0001104659-26-109809.txt | 0001104659-26-109809 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.54 (−2.75%) |
Sep 14, 2026 6w ago | 8-K | $5.55 $3.63 | ▼ −34.59% | ▼ −36.86% | $3.54 (−36.22%) |
Jul 20, 2026 14w ago | 8-K | $5.06 $4.48 | ▼ −11.46% | ▼ −15.58% | $3.54 (−30.04%) |
May 13, 2026 23w ago | 8-K | $8.20 $7.58 | ▲ +7.56% | ▲ +6.70% | $3.54 (+56.83%) |
Apr 27, 2026 26w ago | 8-K | $11.00 $8.17 | ▼ −25.73% | ▼ −30.68% | $3.54 (−67.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers